knowledge -WSS

knowledge

author：comprehensive 2025-09-30 22:55:11 - browse：8697

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Why Charlie Gard's case is so disturbing to Americans

leisure time

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Liquid biopsy for lung cancer is launched by Delfi

AI can decode, harness the power of the humane immune system

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Phenylephrine and the overlooked value of the placebo effect

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

What health policies could hitch a ride on a spending bill?

Drug repurposing or repositioning? The language matters

Healthy food access boosts outcomes in two studies

At least 13 dead in Texas as scorching temps continue

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

At least 13 dead in Texas as scorching temps continue

Ohio still needs to do more to protect the right to abortion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Experimental asthma app from Apple and Anthem shows promise

focus

After decades in use, heart stents finally beat placebo

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Physician executives need more than on

FDA authorizes Novavax’s updated Covid

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Readout Newsletter: Zepbound, Valneva's vaccine, and more

hotspot

entertainment

leisure time

hotspot